Dexcom (DXCM)Director sold ~$69K

~$69K

Approx. value · 1,012 sh @ $68.01

26K

Holds after · shares reported

Traded

Feb 12, 2026

Filed

Feb 17, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Dec 17, 2025FDAFDA device clearance: Dexcom G7 Continuous Glucose Monitoring (CGM) System, Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System
2. Dec 19, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“As previously reported on the Current Report on Form 8-K filed on July 30, 2025, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) appointed Jacob S. Leach, President and Chief Operating Officer, as the President and Chief Executive Officer and as a director of the Company, effective January 1, 2026, following Kevin R. Sayer’s resignation, effective as of such date.”
3. Jan 7, 2026Company filing · Form 8-K · ResultsReported its results
4. Jan 26, 2026CongressDisclosed purchase of DXCM — reported range $1,001 - $15,000
5. Feb 3, 2026FDAFDA device clearance: Dexcom G7 Continuous Glucose Monitoring (CGM) System; Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System
6. Feb 12, 2026 · this disclosureInsiderDirector sold ~$69K of DXCM shares in the open market

What came next

1. Feb 12, 2026Company filing · Form 8-K · ResultsReported its results
2. Feb 26, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On February 26, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”), pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to twelve directors and appointed Albert F. (“Rick”) Osterloh, IV as a director effective immediately.”
3. Feb 27, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“As previously reported on the Current Report on Form 8-K filed on July 30, 2025, Kevin R. Sayer notified the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) of his intent to retire from his role as Chief Executive Officer effective January 1, 2026.”
4. Mar 16, 2026InsiderOfficer sold ~$110K of DXCM shares in the open market
5. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
6. Apr 14, 2026FDARecall: Brand Name: Dexcom G7 Continuous Glucose Monitoring System Product Name: Dexcom G7 CGM watchOS App Model/Catalog Number: SW13355 Software Version: Versions 2.9…
7. Apr 14, 2026FDARecall: Brand Name: Dexcom G7 Continuous Glucose Monitoring System Product Name: Dexcom G7 CGM iOS App Model/Catalog Number: SW12300 Software Version: Versions 2.9.0 t…
8. Apr 14, 2026FDARecall: Brand Name: Dexcom ONE+ Continuous Glucose Monitoring System Product Name: Dexcom ONE+ iOS CGM App Model/Catalog Number: SW14244 Software Version: versions 1.5…
9. Apr 15, 2026InsiderOfficer sold ~$107K of DXCM shares in the open market
10. Apr 29, 20265% stakeVanguard Portfolio Management reported a passive stake (13G) of 5.0%
11. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
12. Apr 29, 2026CongressDisclosed partial sale of DXCM — reported range $100,001 - $250,000
13. Apr 30, 2026Company filing · Form 8-K · ResultsReported its results
14. May 7, 2026CongressDisclosed sale of DXCM — reported range $100,001 - $250,000
15. May 12, 2026InsiderDirector sold ~$61K of DXCM shares in the open market
16. May 15, 2026InsiderOfficer sold ~$102K of DXCM shares in the open market
17. May 21, 2026FDAFDA device clearance: Stelo Glucose Biosensor System
18. May 21, 2026InsiderChair sold ~$1.93M of DXCM shares in the open market
19. May 27, 2026FDARecall: Brand Name: Dexcom G7 Continuous Glucose Monitoring System Product Name: Dexcom G7 US Retail Sensor/Transmitter 1-pack Model/Catalog Number: STP-AT-012 Softwar…
20. Jun 3, 2026InsiderOfficer sold ~$359K of DXCM shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Dexcom

For Dexcom, OQRO holds 20 insider filings (SEC Form 4 or Form 144) and 16 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DXCM page.

Other recent filings by Bridgette P Heller, Director

• SEC Form 4 at Dexcom (DXCM)Aug 13, 2026
• SEC Form 4 at Dexcom (DXCM)May 14, 2026
• SEC Form 4 at Dexcom (DXCM)Nov 12, 2025
• SEC Form 4 at Dexcom (DXCM)Mar 19, 2025
• SEC Form 4 at Dexcom (DXCM)Dec 17, 2024

The full history of Bridgette P Heller, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Dexcom

• SEC Form 4Sep 30, 2026
• SEC Form 144Sep 28, 2026
• SEC Form 4Sep 16, 2026
• SEC Form 4Sep 16, 2026
• SEC Form 4Sep 16, 2026
• SEC Form 144Sep 15, 2026

Everything OQRO holds on this company is on its DXCM page.